Market research
NTP.F Abliva AB (publ)
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 64M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.74
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- SE0002575340
- Market cap
- 64M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.74
About
About Abliva AB (publ)
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden. As of February 7, 2025, Abliva AB (publ) operates as a subsidiary of Pharming Technologies B.V.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NTP.F discussion.
5 years, 5 months ago
Abliva AB (publ) is currently in a long term downtrend where the price is trading 10.0% below its 200 day moving average.
From a valuation standpoint, the stock is 33.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 880.6.
Abliva AB (publ)'s total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 62.8% to $-10M since the same quarter in the previous year.
Finally, its free cash flow grew by 47.2% to $-11M since the same quarter in the previous year.
Based on the above factors, Abliva AB (publ) gets an overall score of 3/5.